文献速递糖尿病

妊娠期糖尿病与表观遗传机制:从受孕到出生如何影响子代 epigenome 与远期疾病风险

Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child's epigenome and later risk of disease.
PubMed 文献 · Lancet Diabetes Endocrinol · 2019-05-22

妊娠期糖尿病不仅增加妊娠并发症和母亲远期代谢病风险,也增加子代远期代谢病风险。宫内建立的表观遗传变异可能是宫内环境与远期疾病易感性之间的合理桥梁。识别与子代代谢健康相关的妊娠期糖尿病表观遗传指纹,或可在代谢功能障碍发生前识别高危子代,用于靶向监测和干预。

要点

  • 妊娠期糖尿病增加子代远期代谢病风险。
  • 宫内表观遗传变异可能是宫内环境与远期疾病易感性之间的桥梁。
  • 识别妊娠期糖尿病表观遗传指纹或有助于早期识别高危子代。

核心结论

  • 妊娠期糖尿病与子代远期代谢病风险增加相关,宫内表观遗传变异可能是其机制之一。

研究设计与样本

  • 本文为 Personal View,未报告系统检索范围或样本量。

主要发现

  • 妊娠期糖尿病不仅与妊娠并发症和母亲后续代谢病风险增加相关,也与子代远期代谢病风险增加相关。

临床怎么用

  • 识别妊娠期糖尿病的表观遗传指纹可能为识别高危子代提供新型生物标志物,以便在代谢功能障碍发生前进行靶向监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. The identification of an epigenetic fingerprint of diabetes in pregnancy linked to the metabolic health of the offspring might provide novel biomarkers for the identification of offspring most at risk, before the onset of metabolic dysfunction, for targeted monitoring and intervention. In this Personal View, we (1) highlight the scale of the problem of diabetes in pregnancy, (2) summarise evidence for the variation in offspring epigenetic profiles following exposure to diabetes in utero, and (3) outline potential future approaches to further understand the mechanisms by which exposure to maternal metabolic dysfunction in pregnancy is transmitted through generations.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Hjort L, Novakovic B, Grunnet LG, et al. Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child's epigenome and later risk of disease. Lancet Diabetes Endocrinol. 2019. PMID: 31128973. doi:10.1016/S2213-8587(19)30078-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。